Australia · Delayed Price · Currency is AUD ReNerve Statistics
Total Valuation
ReNerve has a market cap or net worth of AUD 12.23 million. The enterprise value is 10.95 million.
| Market Cap | 12.23M |
| Enterprise Value | 10.95M |
Important Dates
The last earnings date was Friday, September 11, 2026.
| Earnings Date | Sep 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ReNerve has 172.30 million shares outstanding. The number of shares has increased by 28.95% in one year.
| Current Share Class | 172.30M |
| Shares Outstanding | 172.30M |
| Shares Change (YoY) | +28.95% |
| Shares Change (QoQ) | +16.27% |
| Owned by Insiders (%) | 27.04% |
| Owned by Institutions (%) | 3.66% |
| Float | 92.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.97 |
| PB Ratio | 3.85 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.13, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.13 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -586.58 |
Financial Efficiency
Return on equity (ROE) is -133.13% and return on invested capital (ROIC) is -95.01%.
| Return on Equity (ROE) | -133.13% |
| Return on Assets (ROA) | -75.92% |
| Return on Invested Capital (ROIC) | -95.01% |
| Return on Capital Employed (ROCE) | -203.54% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.65% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.65% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.10 |
| Relative Strength Index (RSI) | 48.33 |
| Average Volume (20 Days) | 73,593 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ReNerve had revenue of AUD 510,357 and -5.57 million in losses. Loss per share was -0.04.
| Revenue | 510,357 |
| Gross Profit | 271,324 |
| Operating Income | -6.52M |
| Pretax Income | -5.57M |
| Net Income | -5.57M |
| EBITDA | -6.49M |
| EBIT | -6.52M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 1.49 million in cash and 201,554 in debt, with a net cash position of 1.29 million or 0.01 per share.
| Cash & Cash Equivalents | 1.49M |
| Total Debt | 201,554 |
| Net Cash | 1.29M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 3.18M |
| Book Value Per Share | 0.02 |
| Working Capital | 2.83M |
Cash Flow
In the last 12 months, operating cash flow was -5.80 million and capital expenditures -73,671, giving a free cash flow of -5.87 million.
| Operating Cash Flow | -5.80M |
| Capital Expenditures | -73,671 |
| Depreciation & Amortization | 30,473 |
| Net Borrowing | -158,490 |
| Free Cash Flow | -5.87M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 53.16% |
| Operating Margin | -1,276.81% |
| Pretax Margin | -1,091.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ReNerve does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.95% |
| Shareholder Yield | -28.95% |
| Earnings Yield | -45.55% |
| FCF Yield | -48.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ReNerve has an Altman Z-Score of -2.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.06 |
| Piotroski F-Score | 1 |